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care of the pheresis catheter; (3) describe the standards for dosing,
frequency, and administration of GCSF; (4) provide education
about the possible side effects of granulocyte donation and how
they may be prevented; (5) describe the potential emotional impli-
cations for the donor.
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NURSING CONSIDERATIONS FOR BMT PHOTOPHERESIS PATIENTS
Rhodes, B.A. M. D. Anderson Cancer Center, Houton, TX.
Graft-versus-Host Disease (GVHD) is a common complication and
limitation of allogeneic hematopoietic stem cell transplantation.
GVHD has a profound impact on the patient’s quality of life and long
term survival rate. Conventional therapy for GVHD is often associ-
ated with signiﬁcant side effects and treatment related complications.
Research is ongoing to ﬁnd better ways to treat GVHD. One treat-
ment modality that appears promising is photopheresis or extracor-
poreal photochemotherapy. Recent studies have shown photopheresis
to have efﬁcacy for the treatment of GVHD of skin, liver, lung, oral
mucosa, and eyes. Photopheresis is an immunomodulatory therapy
that utilizes the leukapheresis of white blood cells, methoxsalen, and
ultraviolet light. Photopheresis was approved by the Food and Drug
Administration in 1988 for the treatment of Cutaneous T-Cell Lym-
phoma. Many photopheresis procedures have been successfully per-
formed on this patient population without complications. The BMT
patient with GVHD is a complex patient with issues such as anemia,
thrombocytopenia, and immunosuppression. These issues can in-
crease the complexity and complications of any procedure. Our center
currently performs approximately 150 photopheresis treatments per
month. Nursing guidelines have been established to minimize and
prevent complications to provide a safe and effective treatment for this
complex patient population. Patient education, order sets, progress
notes, and procedure worksheets were also developed to streamline
the procedure. Photopheresis appears to be an exciting and promising
therapy for the treatment of some forms of GVHD. Nursing guide-
lines and interventions can make a difference to ensure a successful
photopheresis treatment.
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ACUTE HYPERTENSIVE CRISIS DURING INFUSION OF HEMATOPOIETIC
PROGENITOR CELL FROM MATCHED UNRELATED DONORS: IDENTIFI-
CATION OF PREDICTIVE FACTORS AND OPTIMAL TREATMENT
Blackburn, R.K., Giralt, S.A., Saliba, R.M., Rondon, G., Fenwick, J.N.
UTMDACC, Houston, TX.
Background: Acute hypertensive crisis during autologous hemato-
poietic progenitor cell (HPC) infusions using DMSO is widely re-
ported, but the literature is silent regarding this event during infusions
of HPC from matched unrelated donors (MUD). MUD-HPC infu-
sions are often given by evening nursing staff when there is less clinical
support in the hospital, and treatment varies with physician prefer-
ence. Identiﬁcation of predictive factors and of optimal treatment may
lead to improved outcomes. Purpose: To identify predictive factors
for the development of acute hypertensive crisis, and to develop best
treatment pathways. Methods: A retrospective review of 97 adult
patients receiving MUD HPC infusions from October 2003 to Sep-
tember 2004 was done. Demographic, clinical, and laboratory factors
were evaluated for the occurrence of hypertensive crisis using regres-
sion analysis. This analysis was limited to patients receiving HPC-
marrow infusions because only 2/20 cases occurred among patients
receiving PBSC. Hypertensive crisis was deﬁned as SBP 	 160,
DBP 	 100, or a symptomatic increase in BP of 20 mm HG 	
baseline.Results:On univariate analysis, volume infused (adjusted for
weight), elevated creatinine (	1.0 mg/dl), and BUN levels above the
median (	15 mg/dl) were signiﬁcant predictors. Because of high
correlation between BUN and creatinine, only BUN was considered
in multivariate analysis (higher precision associated with the estimate).
Patients receiving high volume infusions with an elevated BUN were
at the greatest risk (62%), followed by patients receiving high volume
infusions and low BUN (28%), and then by patients receiving low
volume and high BUN (17%). There were no cases of hypertension
among the 18 patients who received low volumes and had a low BUN.
Medical treatment during hypertensive episodes varied but best re-
sponses were seen with combined use of IV antihypertensive agents
and diuretics. Recommendations: These ﬁndings suggest that vol-
ume reduction of HPC-M may decrease the incidence of acute hy-
pertensive crisis during MUD infusions (Table 1).
Table 1. Patient Characteristics
Continuous
variables Number
Yes HTN
Crisis
No HTN
Crisis
p
value OR
95%
CI
Age 49 (25-67) 49 (23-71) 0.9
Prior Chemo 2 (0-11) 2.5 (0-9) 0.7
Volume Infused/
Weight 20 (4-29) 6 (0.6-25) 0.001
<4 20 1 (5%)
4-9 16 2(12%)
10-20 18 6 (33%)
>20 16 9 (56%)
<9 36 3 (8%)
>9 34 15 (44%) 0.002 8.7 2.2-33.9
Weight at infusion 79 (59-119) 88 (56-158) 0.2
WBC 0.85 (0.1-5.3) 0.7 (0-15) 0.7
HGB 10.4 (7.9-14) 9.4 (7.4-8.6) 0.26
Hct 30 (22-44) 26 (20-38) 0.1
Plt 59 (4-336) 51 (1-222) 0.9
Acg 0.23 (0-5) 0.68 (0-6) 0.14
Na 139 (136-145) 139 (132-144) 0.3
K 4.1 (2.9-6.3) 3.9 (3.2-5.4) 0.7
Cl 105 (101-115) 107 (99-113) 0.9
CO2 27 (20-32) 27 (21-56) 0.7
Alb 3 (2.2-4.1) 3.1 (2.3-8.8) 0.5
Creatinine 0.95(0.5-2.8) 0.8 (0.5-2.1) 0.03
<1 57 11 (19%)
>1 13 7 (54%) 0.02 4.9 1.4-17
BUN 19 (11-67) 15 (6-71) 0.03
<12 19 2 (11%)
13-15 17 3 (18%)
16-21 19 8 (42%)
>21 15 5 (33%)
<15 36 5 (14%)
>15 34 13 (13%)
Tacro levels 11.5 (3.7-30) 10 (3.1-22.7) 0.3
Categorical
variables
Male 39 10 29
Female 31 8 23 0.9 ref. 1 0.3-2-9
Prior Allo 62 17
No Prior Allo 5 0 5
Prior Auto 11 4 7 0.4 ref 1.9 0.5-7.5
No Prior Auto 56 13 43
Hx of HTN 12 3 9
No Hx HTN 58 15 43 0.9 ref 0.9 0.2-4.0
Hx Diabetes 9 3 6 0.6 ref 1.5 0.3-6.9
No Hx Diabetes 61 15 46
Hx Cardiac Dis 14 5 9 0.3 1.8 0.5-6.5
No Hx Cardiac
Disease 56 13 43
Hx surgery 32 7 25 0.5 ref 0.7 0.2-2.0
No Hx Surgery 38 11 27
Hx Renal disease 4 2 2 0.3 3.1 0.4-24
No Hx Renal dis 66 16 50
Diuretics Used 5 1 4 0.8 0.7 0.1-6.8
No diuretics used 65 17 48
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THE RISK OF GRAFT-VERSUS-HOST DISEASE (GVHD) VARIES WITH
DIFFERENT MYELOABLATIVE REGIMENS: IV BUSULFAN/FLUDARABINE
(IV BuFlu) VERSUS IV BUSULFAN/CYCLOPHOSPHAMIDE (IV BuCy)
VERSUS FLUDARABINE/MELPHALAN (FM)
Mickler, K.L., Saliba, R., Ghosh, S., de Lima, M., Giralt, S., Kim, S.,
Andersson, B., Khouri, I., Champlin, R.E., Couriel, D. The University
of Texas M.D. Anderson Cancer Center, Houston, TX.
Objective: To compare the incidence of GVHD and non-re-
lapse mortality (NRM) among different myeloablative preparative
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